proposed in non-small cell lung cancer studies that combining HIF1α inhibitors with programmed cell death protein 1 (PD-1) antibodies enhances T-cell infiltration, suggesting potential dual antitumor effects of targeting HIF1α (44). This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.